Ignite Creation Date:
2025-12-24 @ 12:53 PM
Ignite Modification Date:
2025-12-24 @ 12:53 PM
Study NCT ID:
NCT04040361
Status:
UNKNOWN
Last Update Posted:
2022-04-06
First Post:
2019-07-29
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
Sponsor:
Masahiro Tsuboi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-29
First Submit QC Date:
None
Study First Post Date:
2019-07-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-04
Last Update Post Date:
2022-04-06
Last Update Post Date Type:
ACTUAL